Long-term surviving mice treated with the elotuzumab-g2a/anti–PD-1 combination are protected against subsequent tumor rechallenge. (A-B) At day 88 after initial EG7-hSLAMF7 inoculation, a cohort of long-term surviving mice originally treated with 3 doses of the elotuzumab-g2a/PD-1 combination were rechallenged with either EG7-hSLAMF7 (A) or MC38 (B) cells. (C-D) Naive C57BL/6 mice were implanted with the same tumor cells to confirm tumor growth. Groups contained 3 to 4 mice and are from a single experiment. Symbols represent individual data points from individual mice.